SCHEMBL2064992

SCHEMBL2064992

NS(=O)(=O)c1cnc2cccnn12

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TNF P01375 3/20 0.55
MKNK1 Q9BUB5 1/20 0.46
KLK7 P49862 1/20 0.46
DYRK1A Q13627 2/20 0.39
CA1 P00915 5/20 0.37
CA2 P00918 5/20 0.37
CA9 Q16790 4/20 0.37
CA12 O43570 3/20 0.37
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
FTO Q9C0B1 1/20 0.35
TGFBR1 P36897 1/20 0.34
MAPK1 P28482 1/20 0.34
SSTR4 P31391 1/20 0.34
HSD11B1 P28845 1/20 0.34
CDK1 P06493 1/20 0.34
CA14 Q9ULX7 1/20 0.33
LRRK2 Q5S007 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203686 0.83 MKNK1 (0.46) TNFMKNK1KLK7DYRK1APRMT5
SCHEMBL4885869 0.73 CDK1 (0.44) TNFMKNK1KLK7DYRK1ACA1
SCHEMBL2392859 0.72 MKNK1 (0.53) MKNK1KLK7DYRK1APRMT5WDR77
SCHEMBL2065978 0.71 TNF (0.67) TNFCA1CA2CA9CA12
Hydrochloric Acid SCHEMBL16324142 0.71 MKNK1 (0.51) MKNK1KLK7DYRK1APRMT5WDR77
SCHEMBL454803 0.70 TGFBR1 (0.48) MKNK1KLK7DYRK1ATGFBR1SSTR4
SCHEMBL9525882 0.70 TGFBR1 (0.46) TNFTGFBR1ALDH1A1
SCHEMBL16256010 0.69 MKNK1 (0.50) MKNK1KLK7DYRK1APRMT5WDR77
SCHEMBL477032 0.68 MKNK1 (0.53) MKNK1KLK7DYRK1APRMT5WDR77
SCHEMBL22510132 0.68 MKNK1 (0.53) MKNK1KLK7DYRK1APRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436955-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Lario Therapeutics Limited (GB) 2024-10-02 EP disclosed
CN-118317950-A Sulfonamide compounds for the treatment of neurological disorders 拉里奥治疗有限公司 2024-07-09 CN disclosed
WO-2023094830-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed
US-8148524-B2 Process for producing sulfonyl chloride compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-04-03 US disclosed
EP-1932846-B1 METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2010-10-27 EP disclosed
JP-2010143944-A NEW METHOD FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINES SUMITOMO CHEMICAL CO LTD 2010-07-01 JP disclosed
EP-1541575-B1 NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVE SUMITOMO CHEMICAL CO (JP) 2010-03-03 EP disclosed
US-20090247748-A1 PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-10-01 US disclosed
EP-1932846-A1 METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-06-18 EP disclosed
US-7307165-B2 Process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) 2007-12-11 US disclosed
US-7307165-B2 Process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) 2007-12-11 US disclosed
CN-100341875-C Novel process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEM TAKEDA AGRO CO (JP) 2007-10-10 CN disclosed
EP-1541575-A4 NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVE SUMITOMO CHEM TAKEDA AGRO CO (JP) 2007-02-28 EP disclosed
CN-1671707-A Novel process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEM TAKEDA AGRO CO (JP) 2005-09-21 CN disclosed
US-20050171108-A1 Novel process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-08-04 US disclosed
US-20050171108-A1 Novel process for producting imidazo[1,2-b]pyridazine derivative SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-08-04 US disclosed
EP-1541575-A1 NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVE Sumitomo Chemical Takeda Agro Company, Limited (JP) 2005-06-15 EP disclosed
EP-1541575-A1 NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVE Sumitomo Chemical Takeda Agro Company, Limited (JP) 2005-06-15 EP disclosed
WO-2004011466-A1 NOVEL PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171108-A1 Novel process for producting imidazo[1,2-b]pyridazine derivative POR, CBR3, NR2C2 TNF 4860/4885MKNK1 3298/4885KLK7 4439/4885
US-20090247748-A1 PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND SALL4, CLCN2, CLIC1 TNF 4785/4885MKNK1 3848/4885KLK7 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.